Circulating IGF-I concentrations remain elevated long after the growth spurt [14] , suggesting that, in addition to growth, IGF-I may serve to regulate other functions in mature vertebrates. Among such functions, emerging data suggest insulin and IGFs may play a prominant neurophysiological role, particularly in the development and maintenance of the neural circuitry [15] . This, in turn, has led to the hypothesis that a decline in IGF activity contributes to the pathogenesis of diabetic neuropathy [16] . This theory prompted Carsten et al. [17] to predict and find functional neuropathy in the spinal cord in an insulin ablation experiment. Fairly extensive observations now support the hypothesis that insulin and IGF-I may act together on neurons (see Discussion). It is possible, then, that the activity of IGF-I, as well as insulin, is important for support of neurons in diabetes.
The purpose of this study was to (a) add to the emerging evidence showing that disturbance in IGF-I mRNA content is widespread among diabetic tissues, and (b) test whether there is a decline in IGF-I mRNA content in diabetic liver and spinal cord sufficiently early to implicate a role for IGF-I in the development of complications in the nervous system.
Materials and methods
Materials: Oligo(dT)l 8 was obtained from Pharmacia (Piscataway, N.J., USA) and T4 polynucleotide kinase from Bethesda Research Laboratories (Gaithersburg, M.d., USA). Streptozotocin (STZ), porcine insulin, and glucose diagnostic kit 510 were purchased from Sigma Chemical Co. (St. Louis, Mo., USA). Mini-osmotic pump Model 2ML1 was from the ALZA Corp. (Palo Alto, Calif., USA). Sprague-Dawley rats were obtained from Charles River Laboratories, Inc. (Wilmington, Mass., USA) or Harlan (Indianapolis, Ind., USA).
The human cDNA clone pKc~l contains the entire c~-tubulin coding region plus 67 and 173 base pairs of the 5' and 3' untranslated regions, respectively [18] . The clone pMH921 is a genomic 2.6 kilobase insert containing the complete coding region of the mouse histone 3.3 gene [19, 20] . The IGF-I cDNA clone in pUC9 was a gift from Dr. A. Efstratiadis and contains the entire rat pre-pro-IGF-I coding sequence plus 340 nucleotides of 5', and 69 nucleotides of 3', non-coding sequence. This clone begins with nucleotide 1780 of exon 1, contains no nucleotides from exon 4, and ends in nucleotide 718 of exon 5 of the sequence published by Shimatsu and Rotwein [21] .
Experimental procedure. All studies involving rats were done in accordance with the principles of the NIH Guide for the Care and Use of Laboratory Animals. Rats were raised on 20 g per day standard rat chow until the study, and chow and water were provided ad libitum thereafter. Male rats (10 or 12-week-old) were randomly assorted into treatment groups, fasted overnight and anaesthesized with 80 mg/kg ketamine and 0.3 mg/kg acepromazine, i.p. Diabetes was induced in 12-week-old rats with i.v. 40-50 mg/kg STZ. STZ lots can have slightly different activity. Control rats were injected with an equivalent volume (1 ml/kg) of vehicle (10 mmol/1 sodium citrate, 0.9 % sodium chloride, pH 4.5). Plasma glucose concentrations were determined the following day using a glucose diagnostic kit. Only STZ-treated rats with greater than 22 mmol/l (400 mg/dl) glucose in plasma were used in this study, except in the insulin infusion study for reasons discussed.
Miniosmotic pumps were implanted s.c. in the midback of some groups the day after STZ administration. The conditions were similar to those described to maintain normoglycaemia during constant insulin infusion [22] . The pumps were filled with either vehicle (1.6 % glycerin, 7 mg/ml glutamic acid, 0.2 % phenol, pH 3.3), or vehicle containing porcine insulin. The solutions were sterilized by passage through 0.2-~tm filters. Insulin concentrations were adjusted to deliver 58.5 nmol (9.75 units) per kg body weight per day, and filled pumps were soaked in saline at 37 ~ for 2 h prior to implantation in order to decrease the time lag in release of solutions.
Preparation of RNA. Following killing with carbon dioxide, total RNA was immediately extracted from various tissues by the guanidinium thiocyanate procedure of Chomczynski and Sacchi [23] ; LiC1 was used to remove glycogen from liver samples [24] . RNA concentration and purity were estimated by A 260 and 280 nm.
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RNA electrophoresis and transfer to nitrocellulose. Equivalent amounts of RNA (40 ~tg determined from absorbance measurements) were electrophoresed through 0.8 % agarose gels containing formaldehyde, as described [25] . Ethidium bromide staining determined the position of 18S and 28S rRNAs and confirmed that equivalent amounts of undegraded RNA had been loaded. The RNA was transferred to nitrocellulose [26] . Alternatively, samples were heat-treated in formaldehyde, rapidly cooled on ice, and directly loaded (8 ~ug in duplicate) onto high capacity BA85 nitrocellulose using a slot blot filtration device (Schleicher and Schuell, Keene, N.H., USA) similar to that described for dot blots [27] . RNA retention was linear up to at least 10 ~tg/slot.
Hybridization to RNA. Nitrocellulose blots were hybridized to nick-translated [28] 3;P-labelled DNA probes for 16-18 h at 42 ~ Single-stranded DNA probes were labelled to high specific activity using Taq primer extension [291 to study spinal cord RNA. Blots were washed for 45-60 rain each with 2 x wash buffer at 42 ~ 2 x wash buffer at 68 ~ twice with 1 x wash buffer at 68 ~ and 0.5 x wash buffer at 68 ~ Single-strength wash buffer (denoted as l x) contained 150 mmol/1 NaC1, 15 mmol/1 sodium citrate, 10 mmol/1 sodium phosphate, 0.03 % pyrophosphate, and 0.05 % sodium dodecylsulphate, pH 7.0.
The procedure of Harley [30] was followed to end-label oligo(dT)l 8. This reagent was used to measure poly(A) + RNA. The slot blot filters were pre-soaked for 5 min in 5 x SSC (1 x SSC is 150 mmol/1 NaC1, 15 mmol/1 sodium citrate) and then hybridized for 1 h at 30 ~ with 32p-labelled oligo(dT)l s (1.02 nmol) in an 8.0 ml solution containing 5 x SSC, 5 x Denhardts, 10mmol/1 Na2HPO4, l mmol/1 Na2H2P~O7, and 0.125 % sodium dodecylsulphate. The filters were then washed three times for 5 rain in 2 x SSC at 30 ~ Boiling twice for 20 min in water was sufficient to remove all hybridized cDNA, as indicated by autoradiography, and some nitrocellulose blots were rehybridized to various cDNA or oligonucleotide probes.
Autoradiography and densitometry. Autoradiograms were prepared on X-ray film using Cronex Lightning Plus enhancing screens at -70~ scanned on a GS 300 Scanning Densitometer connected to a computer, and data were analysed with the GS360 software package (Hoefer Scientific, San Francisco, Calif., USA). The best fit Gaussian curves were used to determine area under curves (AUC), which are reported in arbitrary units in the Figures and Tables. IGF-I mRNA per total RNA was calculated by dividing the IGF-I mRNA AUC values by total RNA loaded per sample, poly(A) + RNA per total RNA was calculated by dividing the oligo(dT) AUC values by total RNA loaded per sample, and IGF-I mRNA per poly(A) + RNA was calculated by dividing the former by the latter. The linear range for measurements was determined by including a concentration series of RNA in blots, and by taking several autoradiographic exposures of different durations.
Statistical analysis
Statistical calculations were made with Student's t-test. Means and SEM are shown. Rats (12 weeks old) were randomly assigned to two groups, one of which was treated with STZ to induce diabetes. After 8 days, RNA was isolated from the livers of both groups. Equivalent amounts of total RNA were analysed on blots to detect IGF-I mRNAs, poly(A) + RNA and histone 3.3 mRNA (Table1). IGF-I mRNA content was significantly reduced in diabetic liver by about 93 % whether measured relative to total RNA or poly(A) + RNA. In contrast, histone 3.3 mRNA content was reduced to a lesser degree per total RNA, but this difference was not selective because it was not reduced per poly(A) + RNA. The relative mRNA pool size, estimated by the oligo(dT) hybridization, did not change appreciably. The results show that the sharp decline in IGF-I mRNA content in diabetic liver was not shared by the total mRNA pool.
Results

IGF-I mRNA content in liver.
Kinetics of lGF-I rnRNA decline in liven
The rate of loss of IGF-I mRNA may provide clues as to the mechanism, as well as relationship to the decline in circulating IGF-I. The rate at which IGF-I mRNA was lost in RNA from diabetic liver is shown in Figure 1. There was no detectible change in the IGF-I mRNA content on the first day following diabetes induction. Thereafter, there was a 55 % decrease in IGF-I mRNA content between 1 and 2 days, no further change between 2 and 3 days, and a second decline of about 40 % between 3 and 7 days. A spontaneous trend towards recovery between 1 and 10 weeks was seen, but only two animals were assayed at 10 weeks making it difficult to attribute significance to this observation.
Insulin infusion opposes the decline in liver IGF-I
mRNA. The possibility that IGF-I mRNA levels might decline as a result of STZ toxicity to liver cells producing this transcript was investigated (Table 2) . After STZ administration, rats had elevated plasma glucose concentrations at 20 h and were randomly assigned to two treatment groups.
Miniosmotic pumps were implanted subcutaneously 20 h post-treatment, and released either vehicle or insulin at a constant rate in a similar manner to that previously shown to maintain normoglycaemia [22] . RNA was extracted from livers of the two groups of diabetic rats 7 days after STZ administration. RNA was also isolated from a third group consisting of age-matched non-diabetic animals. The IGF-I mRNA levels were much lower in the diabetic rats treated with vehicle relative to untreated, nondiabetic rats. Howe, ver, the IGF-I mRNA content remained significantly higher in the insulin-treated vs the vehicle-treated diabetic group, but did not quite return IGF-I mRNA content to normal despite attainment of nearly normal glucose concentrations. These results unequivocally showed that the decline in IGF-I mRNA levels was not the result of STZ toxicity to liver cells producing this transcript. Insulin was capable of inhibiting the decline in IGF-I mRNA content, even though its infusion was not started until 1 day after the STZ treatment. Rats (12 weeks old) were administered STZ and plasma glucose levels were determined after 20 h. The rats were randomly assigned to two groups, both of which were implanted s.c. with miniosmotic pumps. The pumps delivered either 58.5 nmol insulin, kg body weight 1-day 1 or vehicle only. One week after the diabetes induction, plasma glucose levels were determined, and RNA was purified from liver and analysed for relative IGF-I mRNA content on a Northern blot. A third group of untreated non-diabetic animals were also included.
The rats were not fasted prior to glucose assay because of the possibility of hypoglycaemia in the group receiving continuous insulin infusion. a The AUC of densitometric scans is shown. The values are means + SEM, shown as percentages relative to non-diabetic values, n = number of animals. ND, not determined. Up < 0.0005 between the two diabetic groups. c p < 0.025 between the two diabetic groups
Prior
m e a n in vehicle-treated diabetic rats, and was slightly but not significantly elevated relative to the m e a n in n o r m a l animals. This slight elevation could be traced to two diabetic rats that had relatively high p l a s m a glucose concentrations (9.9 and 10.0 retool/l), and very low I G F -I m R N A levels, despite insulin-treatment. W h e t h e r this was due to p o o r p u m p p e r f o r m a n c e resulting f r o m occlusion or due to other causes is not known.
IGF-I m R N A content in adrenal glands.
To study w h e t h e r I G F -I m R N A content is r e d u c e d in other diabetic tissues, the adrenal glands were e x a m i n e d (Fig. 2) . A n i m a l s were 10 or 12 weeks old at the onset of the study, and were assayed after 5 or 1 0 w e e k s ' diabetes duration. The adrenal I G F -I m R N A s were m o r e a b u n d a n t and a b o u t the s a m e in size as the various transcripts o b s e r v e d in n e o n a t a l brain and muscle, but the content was p r o f o u n d l y reduced in all diabetic adrenal glands (Fig. 2 a) . This aut o r a d i o g r a m was scanned on a densitometer, and there was a significant difference (p < 0.005) between non-diabetic and diabetic samples: 769 + 196 (n = 4), non-diabetic; 99 + 19 (n = 6), diabetic. T h e r e was an 87 % decline in the a m o u n t of I G F -I m R N A relative to total R N A in adrenal glands, which was c o m p a r a b l e to the 93 % decline o b s e r v e d earlier in liver. W h e n data f r o m only the 5-week diabetic rats were considered, the I G F -I m R N A content was also significantly r e d u c e d (p < 0.005). The blot was boiled and rehybridized to 32p-labelled c D N A clone pKctl (Fig.2b) . c~-Tubulin m R N A was increased, rather than decreased, relative to total R N A : 6 6 4 + 5 5 (n = 4), non-diabetic; 948 + 30 (n = 6) diabetic Co < 0.005). mRNAs in adrenal glands. Rats (10 and 12 weeks old) were randomly assorted into two groups, one of which was treated with STZ to induce diabetes. After 5 (lanes 2-9) or 10 (lanes 10 and 11) weeks of diabetes, RNA was isolated from adrenal glands. Equivalent amounts of RNA (40 b~g) from each sample were electrophoresed in 0.8% agarose gels containing formaldehyde. Ethidium bromide staining confirmed that equal amounts of undegraded RNA were present in each lane, and revealed the presence of 18 and 28 S rRNA bands. Following transfer to nitrocellulose, the samples were hybridized to a nick-translated cDNA containing the coding sequence of rat IGF-I. A print of the autoradiogram is shown (a). The mean AUC values were decreased in diabetic animals (p < 0.005). The blot was stripped and rehybridized to nicktranslated cDNA clone pKctl to detect ct-tubulin mRNAs (b). Tubulin mRNA levels (mean AUC values) were elevated in diabetic animals (p < 0.005). C, non-diabetic control; D, diabetic; B, 2-day-old rat brain; M, 4-day-old skeletal muscle Figure 2 were analysed further on a slot blot. The blot was hybridized first to detect IGF-I mRNA, boiled, and rehybridized to detect poly(A) + RNA using 32p-labelled oligo(dT). The relative AUC values in arbitrary units are means _+ SEM (n = number of animals), shown as percentages relative to non-diabetic values. P < 0.0005 between non-diabetic and diabetic groups shown in Table 3 
IGF-I m R N A content in spinal cord. The I G F -I gene
is e x p r e s s e d in r o d e n t CNS [4, 6] . The profile of spinal cord I G F -I m R N A s on N o r t h e r n blots was similar to that of brain. I G F -I m R N A content was reduced in diabetic cord (Fig. 3) . The content of total R N A , p o l y ( A ) + R N A , and I G F -I m R N A was m e a s u r e d in spinal cords f r o m rats which were 12 weeks old at the onset, had b e e n t r e a t e d with 40 mg/kg STZ, and had b e e n diabetic for 8 and 14 days ( Table 4 ). The I G F -I m R N A content was p r o f o u n d l y (50-60 %) and significantly decreased p e r spinal cord and per total R N A in rats that had b e e n diabetic for 8 and 14 days, and significantly d e c r e a s e d per p o l y ( A ) + R N A at 14 days. The total R N A content per spinal cord was not significantly different b e t w e e n non-diabetic and diabetic rats.
Using a slightly higher S T Z c o n c e n t r a t i o n (47 mg/ kg), I G F -I m R N A content per p o l y ( A ) § R N A was found to be significantly r e d u c e d (p < 0.005) in diabetic rats (vehicle) as early as 1 w e e k after induction Rats (12 weeks old) were treated with STZ and implanted with pumps that released either insulin or vehicle, in the same experiment described in Figure 3 . One week after the induction of diabetes, RNA was isolated. Slot blots with equivalent amounts of spinal cord RNA (8 ~g/slot) were hybridized to detect IGF-I mRNA. Blots were stripped and rehybridized to detect poly(A) + RNA. Non-diabetic rats were also studied. The relative AUC values in arbitrary units are means + SEM (n = number of rats) shown as percentages relative to non-diabetic values. a p < 0.005, diabetic (vehicle) vs non-diabetic group. b p < 0.05, diabetic (insulin) vs diabetic (vehicle) group of diabetes at 12 weeks of age (Table 5) . STZ toxicity to spinal cord cells was probably not the cause of this reduction, because the loss of IGF-I mRNAs could be prevented by infusion of insulin from a miniosmotic pump after STZ treatment. IGF-I mRNA content per poly(A) + RNA was significantly increased (p < 0.05) in insulin-treated vs vehicle-treated diabetic spinal cords. On the other hand, the poly(A) + RNA content per RNA in spinal cord was unchanged whether rats were diabetic or treated with insulin. The glucose content was significantly reduced in the insulin-treated (8.9 + 2.2 mmol/1, n = 4) vs vehicletreated (44.9 + 2.9 mmol/1, n = 4) diabetic rats.
Animal weights and glucose concentrations. IGF-I
mRNA content is known to decline in starved animals [11, 12] . Because diabetic animals can weigh less, the effect of diabetes on animals weights and glucose concentrations, under the conditions of this study, was measured. Non-diabetic animals showed 4 % weight gain, but diabetic animals lost about 15 % of their initial weight in 2 weeks. There was a significant (p < 0.05) 20 % decrease in weights of diabetic (349 + 8 g, n = 6 rats) relative to non-diabetic rats (438 + 12 g, n = 6). Glucose concentrations were significantly (p < 0.05) elevated in diabetic (32.9 + 2.1 retool/l, n = 6) relative to non-diabetic (6.2+0.3 mmol/1, n = 6) rats at 2 weeks post-treatment. In another study diabetic rats lost about 6 % (not significant) of their initial weight, and were 17 % lighter (p < 0.05, n --5) than non-diabetic rats, after 8 days.
Discussion
IGF-I mRNA content was substantially and selectively diminished in liver, adrenals, and spinal cord of diabetic rats. Others have previously shown de-D.N. Ishii et al.: Reduced IGF-I mRNA content in diabetic tissues creases in diabetic liver, kidney, heart, and lung [12, 13] . Taken together, these results support the suggestion that a reduction in IGF-I mRNA content is widespread among diabetic tissues. Certain syndromes of diabetes might be explained by this reduction. IGF-I mRNA content in diabetic liver was selectively reduced. The reduction in circulating IGF-I concentration in diabetic rats [31] [32] [33] is likely to be closely tied to the profound fall in liver IGF-I mRNA. It is estimated that the 31 ~g/day produced in liver could account for almost all of the circulating concentration of about 800 ng/ml [8, 34] . In the two 10-week diabetic rats, there appeared to be partial recovery of liver IGF-I mRNA content. This might have resulted from the slow regeneration of pancreatic islet cells, which is well known, but this possibility was not investigated.
IGF-I mRNA content was reduced in adrenal glands of only some rats at 1 and 2 weeks diabetes duration (not shown). However, at 5-10 weeks diabetes, IGF-I mRNA content was consistently and significantly reduced relative to total RNA, poly(A) + RNA, and a-tubulin mRNAs in diabetic adrenal glands. The relative content of poly(A) + RNA in total RNA from this tissue was unchanged.
The presence of IGF-I transcripts in human [35] and rat adrenal glands is consistent with the report that adrenal cells can secrete IGF-I [36] . Insulin and IGF receptors are present on chromaffin cells [36] , suggesting that IGF-I may play an autocrine or paracrine role. The low IGF-I mRNA content in diabetic adrenal glands makes it difficult to avoid the implication of a potential relationship to the reduced epinephrine response to hypoglycaemia in diabetes [37, 38] . Involvement of chromaffin cells might be considered in the context of autonomic neuropathy. It is difficult to cleanly dissect medulla from cortex in the rat, and rat cDNA probes might be inappropriate to hybridize to adrenal RNA from other species because of the possibility of cross-hybridization at lower stringency to other members of the insulin/IGF gene family. Alternatively, in situ hybridization might be attempted. Further study is needed to establish whether the IGF-I mRNA is from cortex, medulla, or both tissues.
Autopsy reveals degeneration of the spinal cord in diabetic patients [39] [40] [41] . Unlike peripheral neuropathy, myelopathy is not presently considered a significant complication in diabetes. However, the case for involvement of the central nervous system is growing. For example, visual and auditory evoked potentials are abnormal early after onset of clinical diabetes [42] . Spinal cord degeneration [43] , including reduction in perikaryal volume of ventral horn neurons [44] , is also found in diabetic rats. Thus, rats may provide a useful experimental model in which to study myelopathy. The present observation of an early biochemical disturbance in IGF-I mRNA con-tent in rat spinal cord adds to this growing list showing that the central nervous system is not spared in diabetes.
IGF-I mRNA content is significantly reduced per tissue, per total RNA, and per poly(A) + RNA in spinal cord from diabetic rats. In a separate experiment (not shown), c~-tubulin mRNA content was unchanged, providing further evidence for the selectivity of the decline in IGF-I mRNAs. These effects are observed after only 1 and 2 weeks of diabetes and rank among the earliest detectable biochemical changes observed in neural tissues.
It is striking that, under the same experimental conditions, conduction velocity is predicted and found to be reduced (at 1 and 2 weeks) in spinal cord of rats rendered diabetic with STZ [17] . A similar rate of decline in conduction velocity is observed in peripheral nerwes. Loss of IGF-I mRNA in liver, as well as in spinal cord, may contribute to neuropathy. Infused IGFs can enhance nerve regeneration [45, 46] , indicating that circulating IGF-I may support the nervous system. From this viewpoint, it may be pertinent that the kinetics of loss of IGF-I mRNA in liver is similar to the rate of decline of conduction velocity in spinal cord and peripheral nerves in a separate study with different animals [17] . Yang et al. [11] found somewhat slower kinetics in younger rats treated with higher STZ doses.
The prediction of Carsten et al. [17] was based on emerging evidence that insulin and IGFs may act together on neurons to support the neural circuitry (for greater detail see [15] ). IGF-I mRNAs are present in brain [6, 7, 21] and spinal cord. Moreover, insulin [48, 49] , IGF-I [50] , and their receptors [51] [52] [53] , are found in the CNS. These factors can support neurite outgrowth in cultured sensory, sympathetic [54] , and motor neurons [55] . Survival of peripheral and central neurons is also supported [54, 56] . IGF-I increases sensory nerve regeneration distances [57] and motor axon sprouting [55] in vivo. Recently, a close correlation has been found between the development and regeneration of neuromuscular synapses and the expression of IGF-I [58] and IGF-II [59] genes.
Insulin and IGFs support neurite outgrowth in part by increasing expression of genes encoding structural proteins of axons and dendrites, such as tubulins [60] and neurofilaments [61] . Microtubules, comprised of tubulin subunits, are long, tubular elements of axons and dendrites contributing both to the cytoskeleton and to rapid anterograde and retrograde transport. The 68 and 170 kDa neurofilament proteins assemble into neurofilaments which form part of the axonal cytoskeleton, and are suggested to regulate the diameter of axons [62] .
These observations may be significant in understanding the pathogenesis of this enigmatic disorder [63, 64] . There can be loss of ganglion cells, de-creased numbers and diameters of axons, diminished transport [65] , and reduced conduction velocity in diabetic neuropathy. These pathological changes might be considered in light of the decline in serum IGF-I, evident when the data are corrected for age in diabetic patients [66] . Rhesus monkeys provide an interesting model of non-insulin-dependent diabetes [67] . Young, lean monkeys begin with normal glucose and insulin levels. As animals age, weight is gained, insulin levels become elevated, and impaired glucose tolerance begins to emerge, which progresses to overt hyperglycaemia. It is striking that serum IGF-I levels are progressively reduced in parallel with these age-dependent changes, but are not correlated with either glycaemic state or insulinaemia. Neuropathy is seen in diabetic rhesus monkeys [68] . A more detailed account of the theory linking IGF activity to the pathogenesis of experimental and clinical diabetic neuropathy will appear elsewhere [16] . Acute episodes in insulin-dependent diabetes are associated both with reduced IGF-I activity and transient neuropathy [69, 70] . At the same time, although these may be contributory factors, it is prudent to consider that diabetes is a complex disorder, and neuropathy is believed by many to arise as a direct or indirect result of hyperglycaemia. Further study of this provocative correlation between IGF activity and neuropathy is needed.
IGF-I protein and mRNA contents in liver probably do not decline as a result of STZ toxicity. For example, the administration of insulin following STZ induction of diabetes can antagonize the decline in both IGF-I mRNA and circulating somatomedin [31, 71] . Moreover, insulin can restore serum IGF-I levels towards normal in pancreatectomized dogs [72] , showing that this capacity of insulin to correct IGF-I concentrations is present in diabetic tissues never exposed to STZ.
Moreover, the IGF-I mRNA content in spinal cord probably did not decline as a result of STZ toxicity. However, one may not entirely exclude the possibility that insulin can increase IGF-I mRNA content in diabetic spinal cord directly, rather than by preventing STZ toxicity. Insulin ameliorated the loss of IGF-I mRNAs that occurred in STZ-treated diabetic rats. Insulin also prevents impairment of conduction velocity in STZ-treated diabetic rats [17] .
The reduced IGF-I mRNA content in liver is due in part to a decline in growth hormone secretion in rats [73] . There is tissue resistance to growth hormone as well, because treatment of diabetic rats with growth hormone does not induce IGF-I [32] . Tissue resistance is not due to a reduction in growth hormone receptor mRNA in liver [12] , and growth hormone binding remains normal in rats diabetic for 1 week, although IGF-I levels are reduced [31] . Much less is known about the basis for the decline in IGF-I mRNA content in diabetic tissues other than liver.
